National Resilience, Inc., said that the Government of Canada will invest $163.8 million, through the Strategic Innovation Fund, in the company’s Ontario-based subsidiary Resilience Biotechnologies Inc. (RBI) to modernize and expand production capacity.
 
This project will help increase manufacturing capacity for vaccines and therapeutics, including novel technologies such as mRNA that are now being used to fight COVID-19. The expansion will build on RBI’s existing strengths as an important biomanufacturing organization in Canada, maintaining 295 existing jobs and create 205 new full-time positions at the Mississauga facility.
 
“Resilience was founded during the pandemic to build a better system for manufacturing complex medicines to fight deadly diseases,” said Rahul Singhvi, CEO, Resilience. “This partnership with the Government of Canada will help prepare Canada for future pandemics and strengthen the country’s biopharmaceutical ecosystem.”
 
The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, said, “The Government of Canada’s top priority is to protect the health and safety of Canadians. Today’s contribution to Resilience Biotechnologies Inc. is another important step to support Canada’s leadership in the life sciences sector and to build future pandemic preparedness. These investments are also creating well-paying jobs and helping to grow Canada’s life sciences ecosystem as an engine for our economic recovery.”
 
RBI, located in Mississauga, is a 136,000 square foot biomanufacturing facility that currently provides process and analytical development, scale up, drug substance and drug product / fill finish manufacturing for a variety of medicines.